Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI
Randomised, double‑blind, placebo‑controlled crossover study (n=40) testing a single oral psilocybin dose (18.2 mg/70 kg) versus placebo in healthy volunteers to model psychosis and assess fMRI/qEEG changes.
Details
This crossover, randomised, double‑blind trial administers a single oral dose of psilocybin and matching placebo to healthy volunteers to model serotonergic psychosis and evaluate brain connectivity using resting and task fMRI and quantitative EEG (qEEG).
Primary outcomes compare regional activity and connectivity changes on fMRI and EEG (LORETA, spectral measures, coherence) between psilocybin and placebo; neuropsychiatric scales (BPRS, ASCs, HRS) will be correlated with imaging findings.
The study is a single‑site EEA CTA sponsored by the National Institute of Mental Health (Czech Republic); planned enrolment per registry was 40 healthy adults.